Ignet

Gene Information

Gene symbol: ABL1

Gene name: c-abl oncogene 1, non-receptor tyrosine kinase

HGNC ID: 76

Synonyms: JTK7, c-ABL, p150

Related Genes

#	Gene Symbol	Number of hits
1	BCR	1 hits
2	CD4	1 hits
3	CD8A	1 hits
4	EIF3A	1 hits
5	HLA-B	1 hits
6	IL12A	1 hits
7	IL2	1 hits
8	ITGAM	1 hits
9	ITGAX	1 hits
10	KIT	1 hits
11	KRT126P	1 hits
12	NKTR	1 hits
13	PDGFRB	1 hits
14	WT1	1 hits

Related Sentences

#	PMID	Sentence
1	1460286	By analytic flow cytometry, the mice immunized with PRP-OMPC demonstrated an increase in large splenocytes expressing the Ag Mac-1 (CD11b, CR3).
2	1460286	By immunohistochemical staining, the cells were identified as macrophages due to expression of Mac-1 and p150,95 (CD11C) Ag.
3	1460286	After PRP-OMPC immunization, severe combined immunodeficient mice also demonstrated significant splenomegaly with an increase in macrophages identified by expression of Mac-1 and MHC class II Ag.
4	10540308	Seven alleles were identified for the polymorphic immunodominant molecule (PIM) locus by using restriction enzymes, and 4 alleles each for the p150 and p104 loci.
5	10815918	Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
6	10815918	The BCR/ABL oncogenic fusion protein transforms normal bone marrow stem cells into neoplastic cells.
7	10815918	Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
8	10815918	The BCR/ABL oncogenic fusion protein transforms normal bone marrow stem cells into neoplastic cells.
9	11495816	Produced from the 2-phenylaminopyrimidine class, a novel synthetic inhibitor, identified as CGP57148 (STI571), inhibits tyrosine kinase activity of c-ABL, BCR-ABL, PDGF-R and c-kit at micromolar concentrations.
10	14564482	The other CTL clone, T1/33, was CD8+ and recognized HLA-B3501 or B3503 complexed with an MCE, RPVASDFEP, derived from the c-abl sequence in proximity to the p210(b3a2) fusion point.
11	16528969	Development of immunity in vaccinated mice was associated with the generation of leukemia specific cytotoxic T lymphocytes (CTLs) and secretion of cytokines TNF-alpha and IFN-gamma.
12	16528969	Cured mice were in molecular remission since Bcr/Abl oncogene could not be amplified from the DNA isolated from the marrow, spleen, or liver of cured mice.
13	17327358	Our methods allow us to prepare "designer" CRCL, utilizing the immunostimulation activity and the carrying capacity of CRCL to quantitatively acquire and deliver exogenous antigenic peptides (e.g., derived from the oncogenic BCR/ABL protein in chronic myelogenous leukemia).
14	18398723	Chronic myeloid leukemia (CML) is a stem cell disease in which BCR/ABL plays an important role as oncoprotein and also as a molecular and immunogenic target.
15	18996422	Histidine at position 1042 of the p150 region of a KRT live attenuated rubella vaccine strain is responsible for the temperature sensitivity.
16	18996422	The ts phenotype of KRT varied drastically on replacement of the p150 gene (encoding a methyltransferase and a nonstructural protease).
17	18996422	Thus, we concluded that one mutation, of the histidine at position 1042 of p150, was essential for the ts phenotype of the KRT strain, and structural proteins of KRT had an additive effect with H1042Y on the ts phenotype.
18	18996422	Histidine at position 1042 of the p150 region of a KRT live attenuated rubella vaccine strain is responsible for the temperature sensitivity.
19	18996422	The ts phenotype of KRT varied drastically on replacement of the p150 gene (encoding a methyltransferase and a nonstructural protease).
20	18996422	Thus, we concluded that one mutation, of the histidine at position 1042 of p150, was essential for the ts phenotype of the KRT strain, and structural proteins of KRT had an additive effect with H1042Y on the ts phenotype.
21	18996422	Histidine at position 1042 of the p150 region of a KRT live attenuated rubella vaccine strain is responsible for the temperature sensitivity.
22	18996422	The ts phenotype of KRT varied drastically on replacement of the p150 gene (encoding a methyltransferase and a nonstructural protease).
23	18996422	Thus, we concluded that one mutation, of the histidine at position 1042 of p150, was essential for the ts phenotype of the KRT strain, and structural proteins of KRT had an additive effect with H1042Y on the ts phenotype.
24	19062160	Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
25	19062160	New, potentially tumor-specific antigens have been described in Bcr/Abl positive leukemias.
26	19062160	Besides the main BCR/ABL hybrid fusion transcripts, a small number of transcripts derived from alternative splicing between BCR exons 1, 13, and 14 with ABL exons 4 and 5 have been identified.
27	19062160	Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
28	19062160	New, potentially tumor-specific antigens have been described in Bcr/Abl positive leukemias.
29	19062160	Besides the main BCR/ABL hybrid fusion transcripts, a small number of transcripts derived from alternative splicing between BCR exons 1, 13, and 14 with ABL exons 4 and 5 have been identified.
30	19062160	Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
31	19062160	New, potentially tumor-specific antigens have been described in Bcr/Abl positive leukemias.
32	19062160	Besides the main BCR/ABL hybrid fusion transcripts, a small number of transcripts derived from alternative splicing between BCR exons 1, 13, and 14 with ABL exons 4 and 5 have been identified.
33	22024730	Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12.
34	22024730	bcr/abl fusion gene is thought to be a promising target for chronic myelogenous leukemia (CML) patients to enhance immune response after attaining complete remission.
35	22024730	In this study, we sought to enhance cellular immunity by co-expression of BCR/ABL and murine IL-12 gene on the tumor cell surface as a glycosyl-phosphatidylinositol (GPI)-form.
36	22024730	In a murine transplant model, the vaccinated mice showed decreased infiltration of leukemia cells and reduced expression of BCR/ABL transcripts and protein in bone marrow cells.
37	22024730	Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12.
38	22024730	bcr/abl fusion gene is thought to be a promising target for chronic myelogenous leukemia (CML) patients to enhance immune response after attaining complete remission.
39	22024730	In this study, we sought to enhance cellular immunity by co-expression of BCR/ABL and murine IL-12 gene on the tumor cell surface as a glycosyl-phosphatidylinositol (GPI)-form.
40	22024730	In a murine transplant model, the vaccinated mice showed decreased infiltration of leukemia cells and reduced expression of BCR/ABL transcripts and protein in bone marrow cells.
41	22024730	Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12.
42	22024730	bcr/abl fusion gene is thought to be a promising target for chronic myelogenous leukemia (CML) patients to enhance immune response after attaining complete remission.
43	22024730	In this study, we sought to enhance cellular immunity by co-expression of BCR/ABL and murine IL-12 gene on the tumor cell surface as a glycosyl-phosphatidylinositol (GPI)-form.
44	22024730	In a murine transplant model, the vaccinated mice showed decreased infiltration of leukemia cells and reduced expression of BCR/ABL transcripts and protein in bone marrow cells.
45	22024730	Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12.
46	22024730	bcr/abl fusion gene is thought to be a promising target for chronic myelogenous leukemia (CML) patients to enhance immune response after attaining complete remission.
47	22024730	In this study, we sought to enhance cellular immunity by co-expression of BCR/ABL and murine IL-12 gene on the tumor cell surface as a glycosyl-phosphatidylinositol (GPI)-form.
48	22024730	In a murine transplant model, the vaccinated mice showed decreased infiltration of leukemia cells and reduced expression of BCR/ABL transcripts and protein in bone marrow cells.
49	23841051	The use of a DNA vaccine encoding the BCR/ABL fusion gene is thought to be a promising approach for patients with chronic myeloid leukemia (CML) to eradicate minimal residual disease after treatment with chemotherapy or targeted therapy.
50	23841051	In this study, our strategy employs genetic technology to create a DNA vaccine encoding the BCR/ABL fusion and human interleukin-2 (hIL-2) genes.
51	23841051	The transcription and expression of the BCR/ABL and hIL-2 genes were found in the injected muscle tissues.
52	23841051	The interferon- γ (IFN- γ ) serum levels were increased, and the splenic CD4(+)/CD8(+) T cell ratio was significantly decreased in the BCR/ABL-pIRES-hIL-2-injected mice.
53	23841051	These results indicate that a DNA vaccine containing BCR/ABL and hIL-2 together may elicit increased in vivo humoral and cellular immune responses in BALB/c mice.
54	23841051	The use of a DNA vaccine encoding the BCR/ABL fusion gene is thought to be a promising approach for patients with chronic myeloid leukemia (CML) to eradicate minimal residual disease after treatment with chemotherapy or targeted therapy.
55	23841051	In this study, our strategy employs genetic technology to create a DNA vaccine encoding the BCR/ABL fusion and human interleukin-2 (hIL-2) genes.
56	23841051	The transcription and expression of the BCR/ABL and hIL-2 genes were found in the injected muscle tissues.
57	23841051	The interferon- γ (IFN- γ ) serum levels were increased, and the splenic CD4(+)/CD8(+) T cell ratio was significantly decreased in the BCR/ABL-pIRES-hIL-2-injected mice.
58	23841051	These results indicate that a DNA vaccine containing BCR/ABL and hIL-2 together may elicit increased in vivo humoral and cellular immune responses in BALB/c mice.
59	23841051	The use of a DNA vaccine encoding the BCR/ABL fusion gene is thought to be a promising approach for patients with chronic myeloid leukemia (CML) to eradicate minimal residual disease after treatment with chemotherapy or targeted therapy.
60	23841051	In this study, our strategy employs genetic technology to create a DNA vaccine encoding the BCR/ABL fusion and human interleukin-2 (hIL-2) genes.
61	23841051	The transcription and expression of the BCR/ABL and hIL-2 genes were found in the injected muscle tissues.
62	23841051	The interferon- γ (IFN- γ ) serum levels were increased, and the splenic CD4(+)/CD8(+) T cell ratio was significantly decreased in the BCR/ABL-pIRES-hIL-2-injected mice.
63	23841051	These results indicate that a DNA vaccine containing BCR/ABL and hIL-2 together may elicit increased in vivo humoral and cellular immune responses in BALB/c mice.
64	23841051	The use of a DNA vaccine encoding the BCR/ABL fusion gene is thought to be a promising approach for patients with chronic myeloid leukemia (CML) to eradicate minimal residual disease after treatment with chemotherapy or targeted therapy.
65	23841051	In this study, our strategy employs genetic technology to create a DNA vaccine encoding the BCR/ABL fusion and human interleukin-2 (hIL-2) genes.
66	23841051	The transcription and expression of the BCR/ABL and hIL-2 genes were found in the injected muscle tissues.
67	23841051	The interferon- γ (IFN- γ ) serum levels were increased, and the splenic CD4(+)/CD8(+) T cell ratio was significantly decreased in the BCR/ABL-pIRES-hIL-2-injected mice.
68	23841051	These results indicate that a DNA vaccine containing BCR/ABL and hIL-2 together may elicit increased in vivo humoral and cellular immune responses in BALB/c mice.
69	23841051	The use of a DNA vaccine encoding the BCR/ABL fusion gene is thought to be a promising approach for patients with chronic myeloid leukemia (CML) to eradicate minimal residual disease after treatment with chemotherapy or targeted therapy.
70	23841051	In this study, our strategy employs genetic technology to create a DNA vaccine encoding the BCR/ABL fusion and human interleukin-2 (hIL-2) genes.
71	23841051	The transcription and expression of the BCR/ABL and hIL-2 genes were found in the injected muscle tissues.
72	23841051	The interferon- γ (IFN- γ ) serum levels were increased, and the splenic CD4(+)/CD8(+) T cell ratio was significantly decreased in the BCR/ABL-pIRES-hIL-2-injected mice.
73	23841051	These results indicate that a DNA vaccine containing BCR/ABL and hIL-2 together may elicit increased in vivo humoral and cellular immune responses in BALB/c mice.
74	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
75	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
76	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
77	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
78	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
79	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
80	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
81	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
82	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
83	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
84	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
85	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
86	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
87	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
88	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
89	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
90	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
91	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
92	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
93	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
94	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
95	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
96	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
97	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
98	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
99	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
100	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
101	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
102	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
103	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
104	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
105	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
106	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
107	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
108	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
109	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
110	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
111	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
112	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
113	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
114	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
115	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
116	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
117	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
118	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
119	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
120	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
121	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
122	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
123	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
124	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
125	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
126	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
127	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
128	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
129	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
130	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
131	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
132	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
133	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
134	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
135	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
136	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
137	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
138	24480037	Serine and proline-rich ligands enriched via phage-display technology show preferential binding to BCR/ABL expressing cells.
139	25243629	The extensively validated WT1/c-ABL ratio was used to normalize increases in WT1 transcript levels.
140	25243629	The WT1/c-ABL transcript ratio of 50 or above yielded 100% specificity and 75% sensitivity reliably predicting future relapse with an observed average of 29.4 days (s.d.=19.8) and a calculated average of 63 days (s.d.=29.3) lead time before morphologic confirmation.
141	25243629	The extensively validated WT1/c-ABL ratio was used to normalize increases in WT1 transcript levels.
142	25243629	The WT1/c-ABL transcript ratio of 50 or above yielded 100% specificity and 75% sensitivity reliably predicting future relapse with an observed average of 29.4 days (s.d.=19.8) and a calculated average of 63 days (s.d.=29.3) lead time before morphologic confirmation.